PTIX (Protagenic Therapeutics) Additional Paid-In Capital : $37.79 Mil(As of Mar. 2025)

View and export this data going back to 2003. Start your Free Trial

What is Protagenic Therapeutics Additional Paid-In Capital?

Protagenic Therapeutics's quarterly additional paid-in capital increased from Sep. 2024 ($35.60 Mil) to Dec. 2024 ($37.45 Mil) and increased from Dec. 2024 ($37.45 Mil) to Mar. 2025 ($37.79 Mil).

Protagenic Therapeutics's annual additional paid-in capital increased from Dec. 2022 ($33.37 Mil) to Dec. 2023 ($34.56 Mil) and increased from Dec. 2023 ($34.56 Mil) to Dec. 2024 ($37.45 Mil).

Protagenic Therapeutics Additional Paid-In Capital Historical Data

The historical data trend for Protagenic Therapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Protagenic Therapeutics Additional Paid-In Capital Chart

Protagenic Therapeutics Annual Data

Trend

Jun15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Additional Paid-In Capital

Get a 7-Day Free Trial

16.72

32.41

33.37

34.56

37.45

Protagenic Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Additional Paid-In Capital	Get a 7-Day Free Trial															34.72	35.03	35.60	37.45	37.79

Protagenic Therapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Protagenic Therapeutics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Protagenic Therapeutics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Protagenic Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Protagenic Therapeutics Inc (NAS:PTIX) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

149 Fifth Avenue, Suite 500, New York, NY, USA, 10010

Website

https://www.protagenic.com

Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.

Executives

Alexander K. Arrow	officer: Chief Financial Officer	PO BOX 3094, REDWOOD CITY CA 94064
Jennifer Buell	director	3 FORBES ROAD, LEXINGTON MA 02421
Brian Corvese	director	C/O ANTIGENICS INC., 162 FIFTH AVENUE, SUITE 900, NEW YORK NY 10010
Robert Benjamin Stein	director	C/O AGENUS INC., 3 FORBES ROAD, LEXINGTON MA 02421
Khalil Barrage	director	149 FIFTH AVENUE, SUITE 500, NEW YORK NY 10010
Gregory Ekizian	director	149 FIFTH AVENUE, SUITE 500, NEW YORK NY 10010
Robert Ziroyan	officer: COO / Interim President	149 FIFTH AVENUE, SUITE 500, NEW YORK NY 10010
Joshua Silverman	director	IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017
Garo H Armen	director, 10 percent owner, officer: See Remarks	3 FORBES ROAD, LEXINGTON MA 02421
Edward J Gildea	director, officer: Chief Executive Officer	C/O CONVERTED ORGANICS INC., 7A COMMERCIAL WHARF WEST, BOSTON MA 02110
David J Horin	officer: Chief Financial Officer	1270 AVENUE OF THE AMERICAS, 16TH FLOOR, NEW YORK NY 10020
Jonathan Schechter	director	C/O ATRINSIC, INC. 1 GRAND CENTRAL PLACE, SUITE 2319, NEW YORK NY 10165
Nathan Yu-gai Fong	officer: Chief Financial Officer	THE ORCHARD ENTERPRISES, INC., 23 E. 4TH ST., 3RD FL., NEW YORK NY 10003
Sharon Siegel	officer: Chief Marketing Officer	C/O ATRINSIC, INC., 469 SEVENTH AVENUE, 10TH FLOOR, NEW YORK NY 10018
Raymond Musci	director, officer: Exec VP, Corporate Development	C/O BRILLIANT DIGITAL ENTERTAINMENT INC, 6355 TOPANGA CANYON BOULEVARD SUITE 520, WOODLAND HILLS CA 91367